Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.69 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.54 |
| ▸ | EED | O75530 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HLA-A | P04439 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151911 | 0.93 | SSTR5 (0.66) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL1151661 | 0.92 | SSTR5 (0.60) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL1152064 | 0.91 | SSTR5 (0.59) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL9697183 | 0.91 | SSTR5 (0.72) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL1152873 | 0.89 | KCNH2 (0.70) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL9869915 | 0.88 | SSTR5 (0.68) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL9697345 | 0.87 | KCNH2 (0.64) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| Oxalic Acid SCHEMBL9631522 | 0.86 | SSTR5 (0.65) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| Oxalic Acid SCHEMBL9631511 | 0.86 | SSTR5 (0.65) | KCNH2NR4A2SSTR5HRH1HRH4 | |
| SCHEMBL9629611 | 0.86 | EED (0.68) | KCNH2NR4A2SSTR5HRH1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-RE33833-E | Intermediates for antihistamines, antiserotonine agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-25 | — | — | US | disclosed |
| US-4820822-A | ANTIHISTAMINE, ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA (BE) | 1989-04-11 | — | — | US | disclosed |
| US-4760074-A | Novel-N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-07-26 | — | — | US | disclosed |
| EP-0099139-B1 | NOVEL N-(BICYCLIC HETEROCYCLYL)-4-PIPERIDINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-02-11 | — | — | EP | disclosed |
| US-4556660-A | ANTIALLERGENS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-03 | — | — | US | disclosed |
| EP-0099139-A2 | Novel N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | KCNH2 2148/4885NR4A2 3277/4885SSTR5 4167/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | KCNH2 2148/4885NR4A2 3277/4885SSTR5 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.